BCAX Latest Headlines

Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

at www.tipranks.com (Wed, 13-May 3:35 AM)

Bicara Therapeutics’ Acquisition Strategy Poses Operational, Financing, and Shareholder Dilution Risks

at www.tipranks.com (Wed, 13-May 2:02 AM)

Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Verrica Pharmaceuticals (VRCA) and Kura Oncology (KURA)

at www.tipranks.com (Tue, 12-May 10:40 PM)

Bicara Therapeutics Inc. (BCAX) Gets a Buy from Morgan Stanley

at www.tipranks.com (Tue, 12-May 6:58 AM)

Analysts’ Top Healthcare Picks: Arrowhead Pharmaceuticals (ARWR), Aura Biosciences Inc (AURA)

at www.tipranks.com (Tue, 12-May 6:30 AM)

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Liquidia Technologies (LQDA) and Bicara Therapeutics Inc. (BCAX)

at www.tipranks.com (Tue, 12-May 6:01 AM)

BCAX Advances Ficerafusp Alfa in HPV-Negative Cancer as Cash Position Strengthens for Multiyear Runway

Market Chameleon (Mon, 11-May 9:21 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Mon, 11-May 1:01 PM)

Tyler Van Buren Reiterates Buy Rating on Ficera, Citing Strong Phase III Momentum and Best-in-Class Potential in HPV-Negative Head and Neck Cancer

at www.tipranks.com (Mon, 11-May 12:47 PM)

Bicara plans Q3 alternative dosing study of ~150–200 patients as it targets mid-2027 interim analysis

at seekingalpha.com (Mon, 11-May 12:01 PM)

Bicara Therapeutics GAAP EPS of -$0.93 misses by $0.28

at seekingalpha.com (Mon, 11-May 8:27 AM)

Bicara Therapeutics Grants Inducement Option for 115,000 Shares at $17.59 as Part of Growth Strategy

Market Chameleon (Wed, 4-Mar 9:30 AM)

BCAX Raises $150 Million in Public Offering to Support Ficerafusp Alfa's Regulatory Push and New Cancer Trials

Market Chameleon (Wed, 25-Feb 9:07 AM)